July 14, 2025- Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows.
CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.
